Genedata At GTC Berlin 2026: Pushing Forward AI In Drug Discovery

By Ada Yee, Genedata

This content is brought to you by Genedata, a Danaher Operating Company.

Foundation models for protein structure, binding, and generative design have advanced quickly, but a model alone does not shorten a discovery program. Takeaways from GTC Berlin 2026 focus on what surrounds the model: the tools, scientific context, and governance that let predictions feed back into lab experiments. Speakers from biopharma and healthcare, including NVIDIA's Kimberly Powell and representatives from Merck and Roche, framed scaling AI as an ecosystem problem as much as an engineering one. The discussion also reaches past R&D into manufacturing and clinical settings, where agentic and physical AI are moving from vision toward practice.

Read the takeaways to see where the conference pointed and what it means for AI in biopharma workflows.